Krystal Biotech, Inc. (KRYS)
- Previous Close
130.33 - Open
130.15 - Bid 94.39 x 200
- Ask 165.37 x 200
- Day's Range
127.66 - 131.50 - 52 Week Range
127.40 - 219.34 - Volume
519,616 - Avg. Volume
340,509 - Market Cap (intraday)
3.774B - Beta (5Y Monthly) 0.78
- PE Ratio (TTM)
31.24 - EPS (TTM)
4.18 - Earnings Date Aug 4, 2025 - Aug 8, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
205.20
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.
www.krystalbio.comRecent News: KRYS
View More
Performance Overview: KRYS
Trailing total returns as of 5/16/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: KRYS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: KRYS
View MoreValuation Measures
Market Cap
3.77B
Enterprise Value
3.16B
Trailing P/E
31.25
Forward P/E
17.61
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
11.68
Price/Book (mrq)
3.82
Enterprise Value/Revenue
9.47
Enterprise Value/EBITDA
22.51
Financial Highlights
Profitability and Income Statement
Profit Margin
37.17%
Return on Assets (ttm)
8.66%
Return on Equity (ttm)
13.90%
Revenue (ttm)
333.45M
Net Income Avi to Common (ttm)
123.96M
Diluted EPS (ttm)
4.18
Balance Sheet and Cash Flow
Total Cash (mrq)
616.85M
Total Debt/Equity (mrq)
0.98%
Levered Free Cash Flow (ttm)
76.74M
Research Analysis: KRYS
View MoreResearch Reports: KRYS
View MoreLowering target price to $148.00
KRYSTAL BIOTECH INC has an Investment Rating of BUY; a target price of $148.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of High; a Growth Subrating of Medium; and a Value Subrating of High.
RatingPrice TargetLowering target price to $153.00
KRYSTAL BIOTECH INC has an Investment Rating of BUY; a target price of $153.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of High.
RatingPrice TargetRaising target price to $188.00
KRYSTAL BIOTECH INC has an Investment Rating of BUY; a target price of $188.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of High.
RatingPrice TargetWhat does Argus have to say about KRYS?
KRYSTAL BIOTECH INC has an Investment Rating of BUY; a target price of $186.000000; an Industry Subrating of High; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of High.
RatingPrice Target